Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
COHANCENSECohance Lifesciences Limited· Pharmaceuticals & BiotechnologyCriticalNegative
Announced Fri, 6 Feb, 2026 · 19:53 IST

USFDA warning letter for Cohance's Hyderabad FDF Unit-I

Regulatory & Legal View source PDFExplain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.4%Reaction day
₹338.90
prior close
₹342.80
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+2.5%-0.2% vs market
Pharmaceuticals peers, median of 159sector+1.8%+0.6% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Smallcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.3
10m
+0.5
15m
+2.2
30m
+1.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.4+2.5-0.2+1.8+0.6
Next day
+4.0+3.1+1.0+2.4+1.7
2d
+4.8+3.2+1.6+2.0+2.8
3d
+3.9+2.4+1.4+1.2+2.7
4d
-8.0+0.8-8.7+0.7-8.7
5d
-9.7+0.7-10.4+0.0-9.7
1w
-4.2+2.0-6.2+0.8-5.0
15d
-10.0-1.8-8.2-4.3-5.7
1m
-16.2-5.0-11.1-5.2-11.0
2m
-5.6-2.3-3.3-2.9-2.7
3m
+41.3+8.8+32.6+4.6+36.7
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences shared details on the USFDA warning letter for its FDF Unit-I facility in Nacharam, Hyderabad. Inspected August 4-12, 2025, it received a Form 483 with 6 observations and was classified as Official Action Indicated. Warning letter received February 4, 2026. No penalty or restriction imposed; response being prepared. US revenues from this facility contributed under 2% of FY25 consolidated revenues, with EBITDA below 1%.

Likely market impact

Regulatory setback but limited financial impact since the facility is under 2% of revenue. Short-term sentiment may turn negative.